Clinical trial
Allogenic Islet Cell Transplantation
NCT00160732 · University of Chicago, Other · Active, not recruiting
Key facts
| NCT number | NCT00160732 |
|---|---|
| Title | Allogenic Islet Cell Transplantation |
| Official title | Allogenic Islet Cells (Human, U. of Chicago) Administered Via Intraportal Infusion; and Immunosuppressive Therapy |
| Lead sponsor | University of Chicago, Other |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug, Procedure |
| Interventions | Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells |
| Enrollment | 50 |
| Start date | Oct 1, 2003 |
| Primary completion | Oct 1, 2030 |
| Completion | Oct 1, 2030 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 8, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: